All News
Filter News
Found 96 articles
-
Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors
6/9/2022
PTC Therapeutics, Inc. announced the election of Alethia Young to the company's Board of Directors.
-
Graphite Bio Announces Participation in Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Graphite Bio, Inc. announced that members of the management team will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4 p.m. ET.
-
The ASGCT's 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.
-
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
5/16/2022
Graphite Bio, Inc. presented preclinical data for GPH102, the company’s differentiated gene replacement program for beta-thalassemia, in an oral presentation at the American Society of Gene and Cell Therapy 25th Annual Meeting.
-
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
5/12/2022
Graphite Bio, Inc. reported recent business progress and first quarter 2022 financial results.
-
Graphite Bio Announces Participation in Upcoming Investor Conferences in May 2022
5/4/2022
Graphite Bio, Inc. announced that members of the management team will participate in fireside chats at the following investor conferences.
-
GPH101 is an investigational next-generation gene-edited autologous hematopoietic stem cell (HSC) therapy.
-
Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease
5/3/2022
Graphite Bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GPH101 for the treatment of sickle cell disease (SCD).
-
Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference
3/28/2022
Graphite Bio, Inc. announced that Josh Lehrer, M.D., M.Phil., chief executive officer of Graphite Bio, and Matthew Porteus, M.D., Ph.D., one of the company’s academic founders, will be featured speakers on the “CRISPR and Beyond: Advancing Gene Editing Techniques” panel at the H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on Wednesday, March 30, 2022, at 4 p.m. ET.
-
Graphite Bio Announces Formation of Scientific Advisory Board
3/23/2022
Graphite Bio, Inc. today announced the formation of its Scientific Advisory Board (SAB), which is initially comprised of four experts in stem cell and cancer biology, cell and gene therapy, hematology and immunology.
-
Ocelot Bio Closes $36 Million Series A Financing, Appoints Katherine Vega Stultz as President and Chief Executive Officer
3/23/2022
Ocelot Bio , Inc. today announced the close of a $36 million Series A financing led by RA Capital Management, Venrock and Vivo Capital and the appointment of Katherine Vega Stultz, an experienced pharmaceutical and biotech executive, as president and chief executive officer.
-
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results
3/21/2022
Graphite Bio today reported recent business progress and fourth quarter and fiscal year 2021 financial results.
-
NGS Market Growth – at a CAGR of 10.9% During Forecast Period 2020-2028
3/14/2022
Increasing prevalence of cancer and reproductive health disorders and evolution of cutting-edge next-generation sequencing (NGS) platforms are among the key factors expected to drive the global market revenue growth.
-
BioSpace Movers & Shakers, March 4
3/4/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference
3/3/2022
Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference.
-
Graphite Bio Appoints Alethia Young as Chief Financial Officer
3/2/2022
Graphite Bio, Inc. today announced the appointment of Alethia Young as chief financial officer.
-
Prenatal Testing and Newborn Screening Market Size worth USD 10.85 Billion by 2027 | Industry Trend –Rising Demand for Non-Invasive Techniques
2/22/2022
The global prenatal testing and newborn screening market is projected to be worth USD 10.85 Billion by 2027, according to a current analysis by Emergen Research.
-
A new report showed the increased funding in 2021 mirrors national data that show accelerated financing in support of new therapies for multiple diseases, driven by COVID-19 concerns.
-
Graphite Bio Announces Participation in Upcoming Investor Conferences - Jan 27, 2022
1/27/2022
Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced participation in the following upcoming investor conferences.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.